Lamivudine Normon

Lamivudine, the active ingredient in Lamivudine Normon, is a nucleoside reverse transcriptase inhibitor (NRTI) presented as an oral tablet for oral use. It treats human immunodeficiency virus (HIV) infection and chronic hepatitis B in adult patients.

GNH USA supplies Lamivudine Normon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU quality standards and is manufactured under GMP conditions.

Lamivudine is employed in antiretroviral therapy and antiviral treatment of hepatitis B, targeting viral replication.

- Human immunodeficiency virus (HIV) infection: suppresses viral replication and improves immune function. - Chronic hepatitis B: reduces viral load and slows disease progression.

Lamivudine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Headache: transient cranial discomfort. - Fatigue: general tiredness. - Diarrhea: loose stools. - Insomnia: difficulty sleeping. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Lactic acidosis: severe metabolic disturbance. - Hepatotoxicity: significant liver enzyme elevation. - Pancreatitis: inflammation of the pancreas. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hypersensitivity: systemic allergic response. - Neutropenia: marked reduction in neutrophil count.

Patients should be evaluated for specific health conditions before initiating therapy.

- Renal impairment: adjust dose based on creatinine clearance. - Hepatic impairment: monitor liver function tests regularly. - Pregnancy: use only if potential benefit outweighs risk. - Breastfeeding: consider infant exposure through milk. - Concomitant NRTIs: assess for additive mitochondrial toxicity. - Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Lamivudine can interact with several agents, requiring clinical attention.

Major Interactions (Avoid): - Didanosine: increased risk of pancreatitis. - Stavudine: heightened peripheral neuropathy risk. - Other NRTIs: potential mitochondrial toxicity.

Moderate Interactions (Monitor Closely): - Alcohol: may exacerbate hepatotoxicity. - Antacids (aluminum, magnesium): may reduce absorption. - Protease inhibitors (e.g., ritonavir): may alter lamivudine plasma levels.